Table 2 Meta-analysis for OS
Comparison | Studies | HR (95%CI) | PA value | I2 | PH-value | Model | |
|---|---|---|---|---|---|---|---|
Overall | 10 | 2.12 (1.61,2.79) | < 0.001 | 72.0 | < 0.001 | R | |
Subgroup | |||||||
Country | Asian | 7 | 2.56 (1.90, 3.44) | < 0.001 | 54.5 | 0.040 | R |
Non-Asian | 3 | 1.39 (1.14, 1.70) | 0.001 | 0.0 | 0.634 | F | |
Sample size | < 200 | 4 | 2.08 (1.46, 2.96) | < 0.001 | 43.3 | 0.152 | F |
> 200 | 6 | 2.16 (1.44, 3.22) | < 0.001 | 81.2 | 0.000 | R | |
Cut-off | < 600 | 4 | 2.24 (1.54, 3.23) | < 0.001 | 45.2 | 0.140 | F |
> 600 | 6 | 2.05 (1.39, 3.04) | < 0.001 | 80.5 | < 0.001 | R | |
HR source | M | 8 | 2.34 (1.70,3.21) | 0.000 | 77.1 | 0.001 | R |
U | 2 | 1.42 (1.10,1.84) | 0.008 | 0.0 | 0.357 | F | |
Cancer type | Cervical cancer | 3 | 2.34 (1.55, 3.50) | < 0.001 | 0.0 | 0.431 | F |
Ovarian cancer | 3 | 2.33 (1.08, 5.04) | 0.032 | 81.7 | 0.004 | R | |
Breast cancer | 4 | 1.98 (1.31, 2.99) | 0.001 | 82.8 | 0.001 | R | |
TNBC | 3 | 2.16 (1.31,3.56) | 0.002 | 78.7 | 0.009 | R | |
Other BC type | 3 | 1.79 (1.29, 2.49) | 0.005 | 0.0 | 0.863 | F | |
Follow-up | < 48 m | 7 | 2.42 (1.66, 3.52) | < 0.001 | 70.9 | 0.002 | R |
> 48 m | 2 | 1.98 (1.16, 3.37) | 0.012 | 72.0 | 0.059 | R | |
Unclear | 1 | 1.34 (1.00, 1.79) | 0.047 | – | – | R | |